-+ 0.00%
-+ 0.00%
-+ 0.00%

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Simply Wall St·11/15/2026 13:06:02
Listen to the news

Today is shaping up negative for Ocular Therapeutix, Inc. (NASDAQ:OCUL) shareholders, with the analysts delivering a substantial negative revision to next year's forecasts. Both revenue and earnings per share (EPS) estimates were cut sharply as analysts factored in the latest outlook for the business, concluding that they were too optimistic previously.

After the downgrade, the twelve analysts covering Ocular Therapeutix are now predicting revenues of US$91m in 2027. If met, this would reflect a huge 81% improvement in sales compared to the last 12 months. Losses are expected to increase slightly, to US$1.57 per share. However, before this estimates update, the consensus had been expecting revenues of US$102m and US$1.41 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts.

Check out our latest analysis for Ocular Therapeutix

earnings-and-revenue-growth
NasdaqGM:OCUL Earnings and Revenue Growth November 15th 2026

There was no major change to the consensus price target of US$25.73, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Ocular Therapeutix's growth to accelerate, with the forecast 61% annualised growth to the end of 2027 ranking favourably alongside historical growth of 3.5% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 8.6% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Ocular Therapeutix to grow faster than the wider industry.

The Bottom Line

The most important thing to note from this downgrade is that the consensus increased its forecast losses next year, suggesting all may not be well at Ocular Therapeutix. Unfortunately, analysts also downgraded their revenue estimates, although our data indicates revenues are expected to perform better than the wider market. The lack of change in the price target is puzzling in light of the downgrade but, with a serious decline expected next year, we wouldn't be surprised if investors were a bit wary of Ocular Therapeutix.

Still, the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Ocular Therapeutix going out to 2028, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.